In Silico Study of Bioactive Compounds from Koro Benguk (Mucuna pruriens (L.) DC.) as Potential Modulators of CYP7A1 for Hypercholesterolemia Therapy
DOI:
10.29303/jpm.v21i2.11676Published:
2026-04-09Downloads
Abstract
Hypercholesterolemia is a major risk factor for cardiovascular diseases and remains a significant global health concern. Cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in the classical bile acid synthesis pathway, plays a crucial role in hepatic cholesterol catabolism and represents a promising therapeutic target for cholesterol regulation. Natural product-derived compounds have attracted increasing attention as potential antihypercholesterolemic agents due to their structural diversity and biological activities. However, studies evaluating phytochemicals from Mucuna pruriens as CYP7A1 modulators remain limited, particularly those integrating molecular docking with pharmacokinetic prediction. Therefore, this study aimed to evaluate the potential of bioactive compounds from Mucuna pruriens as modulators of CYP7A1 using an in silico approach. Twenty-eight phytochemical compounds identified through GC-MS profiling were screened using Lipinski’s Rule of Five. Selected compounds were further analyzed by molecular docking against the CYP7A1 protein (PDB ID: 3DAX), followed by ADMET prediction. Docking protocol validation through redocking of the native ligand showed good conformational agreement at the active site (RMSD < 2 Å), confirming the reliability of the docking parameters. Binding affinity and RMSD were used to evaluate ligand–protein interaction stability. Sterculic acid exhibited the strongest binding affinity with a docking score of −6.6.1 kcal/mol and RMSD of 1.51 Å, slightly stronger than the reference ligand 7-ketocholesterol (−7.335 kcal/mol). Interaction analysis revealed hydrogen bonding with key residues, including Asn126 and Lys98, as well as hydrophobic interactions within the active pocket. Other fatty acid derivatives, including octadecanoic acid and heptadecanoic acid, also showed competitive binding energies. ADMET prediction indicated high intestinal absorption (HIA > 90%), no CYP3A4 inhibition, and low predicted toxicity. These results highlight sterculic acid as a promising CYP7A1 modulator and support the potential of Mucuna pruriens phytochemicals for further molecular dynamics studies and experimental validation in the development of hypercholesterolemia therapy.
Keywords:
CYP7A1; Hypercholesterolemia; Molecular Docking; Mucuna pruriensReferences
K. Lestari, R. Sakhnan, and H. Riau, “The Effect Of Aloe Vera Decoction On Blood Cholesterol Levels Of Obese Respondents Level I,” JURNAL PROTEKSI KESEHATAN, vol. 9, no. 1, pp. 30–36, May 2020, doi: 10.36929/jpk.v9i1.245.
L. Tantoso, A. Halim Santoso, F. Christian Gunaidi, S. Kotska Marvel Mayello Teguh, J. S. Letjen Parman No, and J. Barat, “Penilaian Kolesterol Total dan HDL sebagai Deteksi Dini Risiko Penyakit Kardiovaskular pada Populasi Dewasa di Gereja Asisi Jakarta,” Jurnal Pengabdian Masyarakat Nian Tana, vol. 3, no. 2, pp. 39–45, May 2025, doi: 10.59603/jpmnt.v3i2.873.
E. Jung, S. Y. Kong, Y. S. Ro, H. H. Ryu, and S. Do Shin, “Serum Cholesterol Levels and Risk of Cardiovascular Death: A Systematic Review and a Dose-Response Meta-Analysis of Prospective Cohort Studies,” Int. J. Environ. Res. Public Health, vol. 19, no. 14, p. 8272, Jul. 2022, doi: 10.3390/ijerph19148272.
R. A. Putra, F. Nailufar, and A. A. Novaria, “PENGARUH PEMBERIAN JUS NANAS (ANANAS COMOSUS) DAN WORTEL(DAUCUS CAROTA) TERHADAP KADAR LDL (LOW DENSITY LIPOPROTEIN) PADA PEKERJA DI PT. KANITRA MITRA JAYAUTAMA,” Jurnal Kesehatan Tambusai, vol. 6, pp. 12713–12729, Sep. 2025.
S. M. Grundy et al., “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines,” J. Am. Coll. Cardiol., vol. 73, no. 24, pp. e285–e350, Jun. 2019, doi: 10.1016/j.jacc.2018.11.003.
D. T. Mangunsong, M. Arfania, R. Hamjah, and W. Fariza, “EFEKTIVITAS TERAPI OBAT GOLONGAN STATIN TERHADAP PASIEN DISLIPIDEMIA,” Jurnal Ilmiah Wahana Pendidikan, vol. 9, no. 16, pp. 550–554, Aug. 2023, doi: 10.5281/zenodo.8251366.
D. T. Mangunsong, M. Arfania, R. Hamjah, and W. Fariza, “EFEKTIVITAS TERAPI OBAT GOLONGAN STATIN TERHADAP PASIEN DISLIPIDEMIA,” Jurnal Ilmiah Wahana Pendidikan, vol. 9, no. 16, pp. 550–554, Aug. 2023, doi: 10.5281/zenodo.8251366.
S. Rahmat, N. Nadila, D. Deswita, S. P. Hairani, Y. Yeyen, and E. Ensu, “Identifikasi Senyawa Metabolit Sekunder Sebagai Senyawa Kompleks pada Tanaman Tradisional,” Polygon : Jurnal Ilmu Komputer dan Ilmu Pengetahuan Alam, vol. 3, no. 5, pp. 17–26, Aug. 2025, doi: 10.62383/polygon.v3i5.747.
D. Sowdhanya et al., “Nutritional significance of velvet bean (Mucuna pruriens) and opportunities for its processing into value-added products,” J. Agric. Food Res., vol. 15, no. 2, p. 100921, Mar. 2024, doi: 10.1016/j.jafr.2023.100921.
M. Y. Dimitry, B. A. Marie Therèse, D. M. Josiane Edith, P. A. Emmanuel, A. B. Armand, and N. Y. Nicolas, “Hypolipidemic and antioxidant effects of vegetal milk produced with Mucuna pruriens L. seed in rats fed a high-fat diet,” Heliyon, vol. 8, no. 11, p. e11835, Nov. 2022, doi: 10.1016/j.heliyon.2022.e11835.
H. Liu, P. Pathak, S. Boehme, and J. Y. L. Chiang, “Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis,” J. Lipid Res., vol. 57, no. 10, p. 1831, Oct. 2016, doi: 10.1194/jlr.M069807.
D. Cui et al., “Cholesterol metabolism: molecular mechanisms, biological functions, diseases, and therapeutic targets,” Molecular Biomedicine 2025 6:1, vol. 6, no. 1, pp. 72-, Oct. 2025, doi: 10.1186/s43556-025-00321-3.
M. Yu Cai Lim and H. Kiat Ho, “Pharmacological modulation of cholesterol 7α-hydroxylase (CYP7A1) as a therapeutic strategy for hypercholesterolemia,” Biochem. Pharmacol., vol. 220, no. 1, p. 115985, Feb. 2024, doi: 10.1016/j.bcp.2023.115985.
F. Fadilaturahmah, “EFEK ANTIINFLAMASI DAUN KACANG MIANG (Mucuna pruriens (L.) DC.) TERHADAP MENCIT (Mus musculus) YANG DIINDUKSI KARAGENAN,” Jul. 2021.
W. Tempel et al., “Structural characterization of human cholesterol 7α-hydroxylase,” J. Lipid Res., vol. 55, no. 9, p. 1925, 2014, doi: 10.1194/jlr.M050765.
Y. Cheema, K. J. Linton, and I. Jabeen, “Molecular Modeling Studies to Probe the Binding Hypothesis of Novel Lead Compounds against Multidrug Resistance Protein ABCB1,” Biomolecules 2024, Vol. 14, vol. 14, no. 1, Jan. 2024, doi: 10.3390/biom14010114.
W. Tempel et al., “Structural characterization of human cholesterol 7α-hydroxylase,” J. Lipid Res., vol. 55, no. 9, pp. 1925–1932, Sep. 2014, doi: 10.1194/jlr.M050765.
C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings,” Adv. Drug Deliv. Rev., vol. 46, no. 1–3, pp. 3–26, Mar. 2001, doi: 10.1016/S0169-409X(00)00129-0.
D. E. V. Pires, T. L. Blundell, and D. B. Ascher, “pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures,” J. Med. Chem., vol. 58, no. 9, pp. 4066–4072, May 2015, doi: 10.1021/acs.jmedchem.5b00104.
B. C. Doak, B. Over, F. Giordanetto, and J. Kihlberg, “Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates,” Chem. Biol., vol. 21, no. 9, pp. 1115–1142, Sep. 2014, doi: 10.1016/j.chembiol.2014.08.013.
A. Hakiki, A. Andika, and R. Rahmawati, “Studi Molecular Docking dan Prediksi ADMET Senyawa Turunan Kurkumin Sebagai Inhibitor Kasein Kinase 2-α,” Lumbung Farmasi: Jurnal Ilmu Kefarmasian, vol. 5, no. 2, p. 195, Jul. 2024, doi: 10.31764/lf.v5i2.22563.
D. Kempińska, T. Chmiel, A. Kot-Wasik, A. Mróz, Z. Mazerska, and J. Namieśnik, “State of the art and prospects of methods for determination of lipophilicity of chemical compounds,” TrAC Trends in Analytical Chemistry, vol. 113, pp. 54–73, Apr. 2019, doi: 10.1016/j.trac.2019.01.011.
W. Yang, M. Lipert, and R. Nofsinger, “Current screening, design, and delivery approaches to address low permeability of chemically synthesized modalities in drug discovery and early clinical development,” Drug Discov. Today, vol. 28, no. 9, p. 103685, Sep. 2023, doi: 10.1016/j.drudis.2023.103685.
X.-Y. Meng, H.-X. Zhang, M. Mezei, and M. Cui, “Molecular Docking: A powerful approach for structure-based drug discovery,” Curr. Comput. Aided. Drug Des., vol. 7, no. 2, p. 146, Nov. 2011, doi: 10.2174/157340911795677602.
W. Sherman and R. Friesner, “Glide XP fragment docking and structurebased pharmacophores,” Chemistry Central Journal 2009 3:1, vol. 3, no. 1, pp. P45-, Jun. 2009, doi: 10.1186/1752-153X-3-S1-P45.
C. E. Aruwa, Y. Dweba, O. M. Ayodele, and S. Sabiu, “Modulating Acinetobacter baumannii BfmR (RstA) drug target: Daniellia oliveri compounds as RstA quorum sensing inhibitors,” Comput. Biol. Chem., vol. 117, p. 108413, Aug. 2025, doi: 10.1016/j.compbiolchem.2025.108413.
D. B. Kitchen, H. Decornez, J. R. Furr, and J. Bajorath, “Docking and scoring in virtual screening for drug discovery: methods and applications,” Nat. Rev. Drug Discov., vol. 3, no. 11, pp. 935–949, Nov. 2004, doi: 10.1038/nrd1549.
A. K. Varma, R. Patil, S. Das, A. Stanley, L. Yadav, and A. Sudhakar, “Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing,” PLoS One, vol. 5, no. 8, p. e12029, 2010, doi: 10.1371/journal.pone.0012029.
D. E. V. Pires, T. L. Blundell, and D. B. Ascher, “pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures,” J. Med. Chem., vol. 58, no. 9, pp. 4066–4072, May 2015, doi: 10.1021/acs.jmedchem.5b00104.
License
Copyright (c) 2026 Cleofany Aurhelya Paradhise, Trisna Kumala Sari
This work is licensed under a Creative Commons Attribution 4.0 International License.
The following terms apply to authors who publish in this journal:
1. Authors retain copyright and grant the journal first publication rights, with the work simultaneously licensed under a Creative Commons Attribution License 4.0 International License (CC-BY License) that allows others to share the work with an acknowledgment of the work's authorship and first publication in this journal.
2. Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., posting it to an institutional repository or publishing it in a book), acknowledging its initial publication in this journal.
3. Before and during the submission process, authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website), as this can lead to productive exchanges as well as earlier and greater citation of published work (See The Effect of Open Access).
Downloads
How to Cite
